FDA
-
-
-
-
-
-
-
WAVE Life Sciences (WVE) PT Lowered to $36 at Clear Street
-
-
-
-
-
-
-
Raymond James: 'WVE regains full economic rights to WVE-006 from GSK'
-
-
-
-
-
-
-
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
WAVE Life Sciences (WVE) Announces Fast Track Designation from U.S. FDA for Suvodirsen
-
-
-
-
-
-
-
WAVE Life Sciences (WVE) Commences Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen
-
324,567 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

